

REMARKS

Claims 1, 3, 5, 7, 8, 10, 11, and 13, 15-16 are pending in the application.

Claims 2, 4, 6, 9, 12 and 14 have been cancelled. Claims 1 and 13 have been amended. No new matter has been added.

Claims 13 has been rejected under 35 U.S.C. §112, second paragraph.

Applicants have amended claim 13 to address the misspelling pointed out by the Examiner.

Claims 1 and 14-16 have been rejected under 35 U.S.C. 102(b) as allegedly anticipated by Cremades, et al. Applicants respectfully traverse this rejection.

Claim 1, as amended, is directed to a composition having a neuroprotective amount of pGLU-GLU-PRO-amide in a pharmaceutically acceptable carrier, wherein said neuroprotective amount is an amount of about 4.0 mg/kg to about 10 mg/kg to reduce Glu induced neurotoxicity in brain, spinal cord and/or retina. Cremades et al. describes giving 100 ug to a 35 gm mouse to treat the pituitary gland (which is not a part of the central nervous system). This amounts to about 3 mg/kg dose in Cremades. The currently claimed range of about 4.0-10.0 mg/kg to reduce Glu induced neurotoxicity in brain, spinal cord and/or retina is outside the range of Cremades, et al.


Cremades teaches nothing about formulations necessary for administering a compound to the central nervous system, or any part thereof. Moreover, Cremades et al. states about EEP, “[O]ur understanding of their physiological roles, however, is not yet complete.” (page 63, column 2, lines 3-4.) Hence, Cremades does not anticipate the present invention under 35 U.S.C. 102(b).

Reconsideration is respectfully requested.

Date: *9/4/03* By

Nash & Titus, LLC
3415 Brookeville Road, Suite 1000
Brookeville, MD 20833
(301) 924-9500

Respectfully submitted,



Caroline Nash, Reg. No. 36, 329
for: Elizabeth Arwine, Reg. No. 45,867
U.S. Army Medical Research
and Materiel Command
ATTN: MCMR-JA
Fort Detrick, MD 21702-5012